US stock futures dip as Nvidia earnings spark little cheer
BOSTON—Amy Elazzouzi, the Senior Vice President of Finance at Aura Biosciences , Inc. (NASDAQ:AURA), recently sold shares of the company’s common stock. According to a filing with the Securities and Exchange Commission, Elazzouzi sold 897 shares on April 16, 2025, at a weighted average price of $5.49, totaling approximately $4,924. The transaction comes as InvestingPro data shows the stock has gained 8.65% over the past week, though currently trading below its Fair Value estimate.
These transactions were conducted to cover tax withholding obligations related to the vesting of restricted stock units and were automatic, not discretionary. Following the sale, Elazzouzi holds 81,381 shares of Aura Biosciences. The shares were sold at prices ranging from $5.49 to $5.57, well below analyst targets ranging from $19 to $25. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 10.77 and holds more cash than debt on its balance sheet. Get deeper insights into insider transactions and 8 additional key ProTips with an InvestingPro subscription.
In other recent news, Aura Biosciences has announced promising results from its Phase 1 trial for the investigational drug bel-sar, aimed at treating non-muscle invasive bladder cancer. The trial demonstrated favorable safety and feasibility outcomes, with notable clinical activity observed in patients, including complete responses and tumor shrinkage. Additionally, H.C. Wainwright raised its price target for Aura Biosciences to $25, citing progress in developing bel-sar for early-stage choroidal melanoma and highlighting its potential to fill a significant treatment gap. Meanwhile, JMP Securities adjusted its price target to $19, maintaining a Market Outperform rating while noting positive feedback from Key Opinion Leaders on bel-sar’s early trial results. The company is advancing its lead candidate, bel-sar, through various clinical trials, including a Phase 3 trial for uveal melanoma, which has enrolled over 175 patients. Aura Biosciences also expanded its Board of Directors by appointing Teresa Bitetti, who brings extensive oncology expertise, potentially aiding the company’s growth in the oncology sector. These developments underscore the company’s ongoing efforts to advance its clinical pipeline and explore new treatment avenues.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.